Occudo Quantitative Strategies LP Cuts Position in Glaukos Co. (NYSE:GKOS)

Occudo Quantitative Strategies LP decreased its holdings in Glaukos Co. (NYSE:GKOS) by 42.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,420 shares of the medical instruments supplier’s stock after selling 1,817 shares during the period. Occudo Quantitative Strategies LP’s holdings in Glaukos were worth $363,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of GKOS. Barclays PLC grew its stake in shares of Glaukos by 394.4% in the third quarter. Barclays PLC now owns 89,699 shares of the medical instruments supplier’s stock worth $11,686,000 after acquiring an additional 71,556 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Glaukos by 80.1% in the third quarter. Franklin Resources Inc. now owns 15,621 shares of the medical instruments supplier’s stock worth $2,031,000 after acquiring an additional 6,948 shares in the last quarter. Oak Ridge Investments LLC acquired a new position in shares of Glaukos in the fourth quarter worth $1,672,000. LVW Advisors LLC grew its stake in shares of Glaukos by 22.2% in the fourth quarter. LVW Advisors LLC now owns 2,273 shares of the medical instruments supplier’s stock worth $341,000 after acquiring an additional 413 shares in the last quarter. Finally, Zhang Financial LLC acquired a new position in shares of Glaukos in the fourth quarter worth $221,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Activity

In other news, CFO Alex R. Thurman sold 1,520 shares of the company’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the sale, the chief financial officer now directly owns 53,431 shares of the company’s stock, valued at approximately $5,708,568.04. This represents a 2.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.80% of the company’s stock.

Glaukos Stock Performance

NYSE GKOS opened at $91.68 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos Co. has a 1 year low of $77.10 and a 1 year high of $163.71. The company has a market capitalization of $5.24 billion, a PE ratio of -31.94 and a beta of 0.83. The company has a fifty day moving average of $93.95 and a two-hundred day moving average of $126.28.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. During the same quarter in the prior year, the firm posted ($0.70) earnings per share. Glaukos’s revenue for the quarter was up 24.6% on a year-over-year basis. As a group, analysts expect that Glaukos Co. will post -1.08 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have commented on GKOS. Truist Financial restated a “buy” rating and issued a $135.00 price target (down previously from $140.00) on shares of Glaukos in a research note on Thursday, May 1st. Stephens lowered their target price on shares of Glaukos from $140.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, May 2nd. Mizuho lowered their target price on shares of Glaukos from $200.00 to $175.00 and set an “outperform” rating for the company in a research note on Wednesday, April 16th. Morgan Stanley lowered their target price on shares of Glaukos from $110.00 to $72.00 and set an “underweight” rating for the company in a research note on Tuesday, May 6th. Finally, Piper Sandler lowered their target price on shares of Glaukos from $180.00 to $165.00 and set an “overweight” rating for the company in a research note on Tuesday, April 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $134.67.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.